Tag
Eli Lilly
5 articles
Eli Lilly's Retatrutide Shows 20.8% Weight Loss at Top Dose; BLA Due Q1 2027
Triple agonist achieves dose-dependent weight reductions up to 49.6 pounds and A1C drops to 5.7% in 40% of patients, clearing path for 2027 market entry.
17 S&P 500 Companies Drive Index Returns on Margin Expansion
A core group of 17 S&P 500 constituents is outpacing the broader market through disciplined cost control and expanding profit margins, deepening index concentration since 2020.
Eli Lilly Surges 6.5% on Q2 Beat; Nvidia Holds AI Chip Lead
Eli Lilly topped second-quarter estimates and Nvidia extended its lead in AI chips as broad indexes logged a fifth straight winning session.
AMD, Eli Lilly Earnings Will Test Whether the Rally Can Broaden
The Nasdaq rose 1.0 percent Tuesday while the Russell 2000 fell 0.5 percent, a split that puts pressure on next week's earnings to justify current valuations.
Eli Lilly's Retatrutide FDA Bid Targets $25B Peak Sales in $100B Obesity Market
Lilly's triple-receptor weight-loss drug retatrutide heads to FDA with a 24 percent efficacy edge over rivals and a $1,200 price target from JPMorgan.